Baidu
map

肿瘤指南

订阅

MedSci主页 / 所有栏目 / 肿瘤指南

2022 多学科共识：雄激素剥夺治疗前列腺癌患者骨质疏松和脆性骨折的预防和治疗

2022-01-05 韩国性医学和男科学会 World J Mens Health

骨质疏松前列腺癌脆性骨折雄激素剥夺治疗男科生殖

雄激素剥夺治疗（ADT）前列腺癌（PCa）患者存在骨质疏松和脆性骨折的高风险。本文主要针对这些患者骨质疏松和脆性骨折的预防和治疗提供共识指导建议。

中文标题：

2022 多学科共识：雄激素剥夺治疗前列腺癌患者骨质疏松和脆性骨折的预防和治疗

英文标题：

Multidisciplinary Consensus on the Prevention and Treatment of Osteoporosis and Fragility Fractures in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy

发布机构：

韩国性医学和男科学会

发布日期：

2022-01-05

简要介绍：

雄激素剥夺治疗（ADT）前列腺癌（PCa）患者存在骨质疏松和脆性骨折的高风险。本文主要针对这些患者骨质疏松和脆性骨折的预防和治疗提供共识指导建议。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2022 多学科共识：雄激素剥夺治疗前列腺癌患者骨质疏松和脆性骨折的预防和治疗.pdf)] GetToolGuiderByIdResponse(projectId=1, id=538a01c002313267, title=2022 多学科共识：雄激素剥夺治疗前列腺癌患者骨质疏松和脆性骨折的预防和治疗, enTitle=Multidisciplinary Consensus on the Prevention and Treatment of Osteoporosis and Fragility Fractures in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy, guiderFrom=World J Mens Health, authorId=0, author=, summary=雄激素剥夺治疗（ADT）前列腺癌（PCa）患者存在骨质疏松和脆性骨折的高风险。本文主要针对这些患者骨质疏松和脆性骨折的预防和治疗提供共识指导建议。, cover=https://img.medsci.cn/202216/1641445402492_1608702.jpg, journalId=0, articlesId=null, associationId=2276, associationName=韩国性医学和男科学会, associationIntro=韩国性医学和男科学会(KSSMA,Korean Society for Sexual Medicine and Andrology), copyright=0, guiderPublishedTime=Wed Jan 05 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">雄激素剥夺治疗（ADT）前列腺癌（PCa）患者存在骨质疏松和脆性骨折的高风险。本文主要针对这些患者骨质疏松和脆性骨折的预防和治疗提供共识指导建议。</span></p>, tagList=[TagDto(tagId=646, tagName=骨质疏松), TagDto(tagId=781, tagName=前列腺癌), TagDto(tagId=19798, tagName=脆性骨折), TagDto(tagId=57527, tagName=雄激素剥夺治疗), TagDto(tagId=117054, tagName=男科生殖)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=26, categoryName=泌尿外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21067, categoryName=梅斯医学-骨质疏松网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=57527, guiderKeyword=雄激素剥夺治疗, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=5, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4264, appHits=97, showAppHits=0, pcHits=362, showPcHits=4166, likes=1, shares=12, comments=7, approvalStatus=1, publishedTime=Thu Jan 06 11:06:16 CST 2022, publishedTimeString=2022-01-05, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=dajiong, createdTime=Thu Jan 06 11:09:04 CST 2022, updatedBy=1608702, updatedName=dajiong, updatedTime=Sat Jan 06 21:45:34 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2022 多学科共识：雄激素剥夺治疗前列腺癌患者骨质疏松和脆性骨折的预防和治疗.pdf)])
2022 多学科共识：雄激素剥夺治疗前列腺癌患者骨质疏松和脆性骨折的预防和治疗.pdf
下载请点击：
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1192243, encodeId=7a3611922436e, content=谢谢分享，受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00ef1386847, createdName=lds701, createdTime=Fri Feb 11 11:19:52 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187456, encodeId=7e93118e45687, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f52c6479942, createdName=ms4000002064954291, createdTime=Sun Jan 23 14:00:10 CST 2022, time=2022-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183010, encodeId=bf44118301007, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24335441481, createdName=LUO2020, createdTime=Mon Jan 10 23:19:48 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182651, encodeId=7dcd11826516e, content=学习．, beContent=null, objectType=guider, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4acb6418986, createdName=明日何其多, createdTime=Sun Jan 09 22:45:21 CST 2022, time=2022-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182429, encodeId=44491182429f5, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Jan 09 07:24:09 CST 2022, time=2022-01-09, status=1, ipAttribution=)]
    2022-02-11 lds701

    谢谢分享，受益匪浅

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1192243, encodeId=7a3611922436e, content=谢谢分享，受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00ef1386847, createdName=lds701, createdTime=Fri Feb 11 11:19:52 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187456, encodeId=7e93118e45687, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f52c6479942, createdName=ms4000002064954291, createdTime=Sun Jan 23 14:00:10 CST 2022, time=2022-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183010, encodeId=bf44118301007, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24335441481, createdName=LUO2020, createdTime=Mon Jan 10 23:19:48 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182651, encodeId=7dcd11826516e, content=学习．, beContent=null, objectType=guider, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4acb6418986, createdName=明日何其多, createdTime=Sun Jan 09 22:45:21 CST 2022, time=2022-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182429, encodeId=44491182429f5, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Jan 09 07:24:09 CST 2022, time=2022-01-09, status=1, ipAttribution=)]
    2022-01-23 ms4000002064954291

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1192243, encodeId=7a3611922436e, content=谢谢分享，受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00ef1386847, createdName=lds701, createdTime=Fri Feb 11 11:19:52 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187456, encodeId=7e93118e45687, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f52c6479942, createdName=ms4000002064954291, createdTime=Sun Jan 23 14:00:10 CST 2022, time=2022-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183010, encodeId=bf44118301007, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24335441481, createdName=LUO2020, createdTime=Mon Jan 10 23:19:48 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182651, encodeId=7dcd11826516e, content=学习．, beContent=null, objectType=guider, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4acb6418986, createdName=明日何其多, createdTime=Sun Jan 09 22:45:21 CST 2022, time=2022-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182429, encodeId=44491182429f5, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Jan 09 07:24:09 CST 2022, time=2022-01-09, status=1, ipAttribution=)]
    2022-01-10 LUO2020

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1192243, encodeId=7a3611922436e, content=谢谢分享，受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00ef1386847, createdName=lds701, createdTime=Fri Feb 11 11:19:52 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187456, encodeId=7e93118e45687, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f52c6479942, createdName=ms4000002064954291, createdTime=Sun Jan 23 14:00:10 CST 2022, time=2022-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183010, encodeId=bf44118301007, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24335441481, createdName=LUO2020, createdTime=Mon Jan 10 23:19:48 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182651, encodeId=7dcd11826516e, content=学习．, beContent=null, objectType=guider, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4acb6418986, createdName=明日何其多, createdTime=Sun Jan 09 22:45:21 CST 2022, time=2022-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182429, encodeId=44491182429f5, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Jan 09 07:24:09 CST 2022, time=2022-01-09, status=1, ipAttribution=)]
    2022-01-09 明日何其多

    学习．

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1192243, encodeId=7a3611922436e, content=谢谢分享，受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00ef1386847, createdName=lds701, createdTime=Fri Feb 11 11:19:52 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187456, encodeId=7e93118e45687, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f52c6479942, createdName=ms4000002064954291, createdTime=Sun Jan 23 14:00:10 CST 2022, time=2022-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183010, encodeId=bf44118301007, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24335441481, createdName=LUO2020, createdTime=Mon Jan 10 23:19:48 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182651, encodeId=7dcd11826516e, content=学习．, beContent=null, objectType=guider, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4acb6418986, createdName=明日何其多, createdTime=Sun Jan 09 22:45:21 CST 2022, time=2022-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182429, encodeId=44491182429f5, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Jan 09 07:24:09 CST 2022, time=2022-01-09, status=1, ipAttribution=)]
    2022-01-09 微探

    学习学习

    0

相关指南

基层医疗机构骨质疏松症诊断和治疗专家共识(2021)

中国健康促进基金会基层医疗机构骨质疏松症诊断与治疗专家共识委员会 · 2021-07-20

骨转换生化标志物临床应用指南

中华医学会骨质疏松和骨矿盐疾病分会(Chinese Medical Association) · 2021-11-10

症状性陈旧性胸腰椎骨质疏松性骨折手术治疗临床指南

中国骨科相关专家小组（统称） · 2020-07-30

骨质疏松的影像学与骨密度诊断专家共识

中华医学会放射学分会(CSR,chinese society of radiology) · 2020-08-10

围绝经期和绝经后妇女骨质疏松防治专家共识

中国老年学和老年医学学会(CAGG,China Association of Gerontology and Geriatrics) 骨质疏松分会 · 2020-08-10

2020 AACE/ACE临床实践指南：绝经后骨质疏松症的诊断和治疗

美国临床内分泌医师学会(AACE,American Association of Clinical Endocrinologists) · 2020-04-27

拓展阅读

2022 CUA指南：雄激素剥夺治疗—不良事件和管理策略（更新版）

加拿大泌尿外科协会(CUA,Canadian Urological Association) · 2022-08-01

2022 CUA更新指南：雄激素剥夺治疗不良事件和管理策略

加拿大泌尿外科协会(CUA,Canadian Urological Association) · 2021-04-21

Baidu
map
Baidu
map
Baidu
map